US2010137435A1PendingUtilityA1

Monoacetyldiacylglycerol Derivative for the Treatment of Sepsis

61
Assignee: KIM SANG-HEEPriority: Apr 24, 2004Filed: Dec 17, 2009Published: Jun 3, 2010
Est. expiryApr 24, 2024(expired)· nominal 20-yr term from priority
Inventors:Sang Hee Kim
A61P 37/02A61P 37/00A61P 43/00A23L 33/12A61K 9/0019A21D 2/16A23L 2/52A23G 3/364A23L 33/105A61K 9/2018A61K 9/4858A61K 9/0058A23V 2002/00A23G 9/32A23G 4/12A61K 31/22A23G 1/32A23G 9/36A61P 31/04A61P 29/00A23G 4/06A23G 1/42A61K 9/0056A61P 35/00A61K 9/4875A61P 31/18A23G 3/36
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The uses of mono acetyl diacyl glycerol derivatives extracted from deer antler for immunomodulating agent disclosed. Medical supplies and health foods containing the same as an effective ingredient also disclosed. Mono acetyl diacyl glycerol derivatives shows significantly effect for immuno modulation including immune enhancing. In the case of inducing cancer in a hamster by injecting cancer cell line, cancer development was delayed by activating lymphocytes, monocytes, and dendritic cells that are important factors to promote immunity and apoptosis of cancer cell was induced by promoting cytotoxicity of immune cell against caner cell. Also in the case of mouse induced septic shock, it shows 100% survival rate even after lapse of 120 hours by control of immune function and suppression effect of apoptosis. Therefore, mono acetyl diacyl glycerol derivatives according to the present invention can be effectively used for an immunomodulating agent, a sepsis treatment, a cancer treatment, and a health food for an immune modulation or the prevention of cancer.

Claims

exact text as granted — not AI-modified
1 . A method of treating cancer comprising administering to a mammal an effective amount of a mono acetyl diacyl glycerol derivative of formula I: 
       
         
           
           
               
               
           
         
         wherein R1 is 9-octadecenoyl and R2 is hexadecanoyl; 
         R1 is hexadecanoyl and R2 is 9-octadecenoyl; 
         R1 is hexadecanoyl and R2 is 9,12-octadecadiennoyl; 
         R1 is hexadecanoyl and R2 is 9,12,15-octadecatriennoyl; or 
         R1 is hexadecanoyl and R2 is 5,8,11,14-eicosatetraenoyl. 
       
     
     
         2 . The method of  claim 1 , wherein the cancer is selected from the group consisting of bile duct cancer, kidney cancer and malignant melanoma.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.